Austin TX 头颈鳞状细胞癌临床试验
8项针对 头颈鳞状细胞癌的研究正在 Austin及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
招募中1 期
- Exelixis Clinical Site #46, Austin
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
招募中1/2 期
- Texas Oncology (Balcones) - SCRI, Austin
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
招募中1/2 期
- NEXT Oncology Austin, Austin
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
招募中1 期
- NEXT Oncology Austin /ID# 243005, Austin
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
招募中1 期
- NEXT Texas LLC - Austin, Austin
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
招募中1 期
- NEXT Oncology, Austin, TX 78758
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
招募中1 期
- Dren Investigational Site, Austin
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
招募中1/2 期
- Research Site 135, Austin
其他城市的 头颈鳞状细胞癌试验
- Houston, TX47 项研究
- Los Angeles, CA42 项研究
- Boston, MA40 项研究
- New York City, NY39 项研究
- Nashville, TN39 项研究
- St. Louis, MO28 项研究
- Arlington, VA26 项研究
- Chicago, IL26 项研究
- Philadelphia, PA26 项研究
- Atlanta, GA24 项研究
- San Antonio, TX22 项研究
- New Haven, CT22 项研究
Austin的其他研究
- 非小细胞肺癌30 项研究
- 癌症（所有类型）20 项研究
- 肥胖症20 项研究
- 结直肠癌19 项研究
- 转移性癌症19 项研究
- 超重18 项研究
- 心力衰竭18 项研究
- 乳腺癌18 项研究
- 卵巢癌17 项研究
- 子宫内膜癌15 项研究
- 前列腺癌15 项研究
- 抑郁症14 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。